Claims
- 1. A method of treating or preventing an HIV infection in an individual in need thereof, comprising administering to the individual an effective amount of a composition comprising a condensation polymer of an aromatic sulfonic acid and an aldehyde, a pharmaceutically acceptable salt or prodrug thereof in a physiologically acceptable carrier.
- 2. The method of claim 1 wherein the condensation polymer is a condensation polymer of a naphthalene sulfonic acid and formaldehyde.
- 3. The method of claim 2 wherein the condensation polymer is a narrow or mono-dispersed condensation polymer.
- 4. The method of claim 2 wherein the condensation polymer has a peak molecular weight of less than about 50 kDa.
- 5. The method of claim 4 wherein the condensation polymer has a peak molecular weight between from about 0.7 kDa and about 50 kDa.
- 6. The method of claim 5 wherein the condensation polymer has a peak molecular weight between from about 1.3 kDa to about 30 kDa.
- 7. The method of claim 6 wherein the condensation polymer has a peak molecular weight between from about 4 kDa to 12 kDa.
- 8. The method of claim 2 wherein the condensation polymer has an average of between about 0.5 to about 2.0 sulfonic acid groups per aromatic group.
- 9. The method of claim 8 wherein the condensation polymer has an average of about 1 sulfonic acid group per aromatic group.
- 10. The method of claim 2 wherein the condensation polymer has a therapeutic ratio of at least about 7.
- 11. The method of claim 10 wherein the condensation polymer has a therapeutic ratio of at least about 20.
- 12. A method of claim 2 wherein the physiologically acceptable carrier is a contraceptive formulation.
- 13. The method of claim 2 wherein the individual is infected by HIV.
- 14. The method of claim 2 wherein the individual has been exposed to HIV.
- 15. A method of inhibiting or preventing HIV infectivity of CD4+ cells in an individual, comprising administering to the individual an effective amount of a composition comprising a condensation polymer of an aromatic sulfonic acid and an aldehyde a pharmaceutically acceptable salt or prodrug thereof in a physiologically acceptable carrier.
- 16. A method of claim 15 wherein the condensation polymer is a condensation polymer of a naphthalenesulfonic acid and formaldehyde.
- 17. A method of claim 16 wherein the condensation polymer is a narrow or mono-dispersed condensation polymer.
- 18. The method of claim 16 wherein the condensation polymer has a peak molecular weight of less than about 50 kDa.
- 19. The method of claim 18 wherein the condensation polymer has a peak molecular weight between from about 0.7 kDa and about 50 kDa.
- 20. The method of claim 19 wherein the condensation polymer has a peak molecular weight between from about 1.3 kDa to about 30 kDa.
- 21. The method of claim 20 wherein the condensation polymer has a peak molecular weight between from about 4 kDa to 12 kDa.
- 22. The method of claim 16 wherein the condensation polymer has an average of between about 0.5 to about 2.0 sulfonic acid groups per aromatic group.
- 23. The method of claim 22 wherein the condensation polymer has an average of about 1 sulfonic acid group per aromatic group.
- 24. The method of claim 16 wherein the condensation polymer has a therapeutic ratio of at least about 9.
- 25. The method of claim 24 wherein the condensation polymer has a therapeutic ratio of at least about 20.
- 26. A method of claim 16 wherein the physiologically acceptable carrier is a contraceptive formulation.
- 27. The method of claim 16 wherein the individual is infected by HIV.
- 28. The method of claim 16 wherein the individual has been exposed to HIV.
- 29. A method of inhibiting or preventing HIV-induced syncytia formation in an individual, comprising administering to the individual an effective amount of a composition comprising a condensation polymer of an aromatic sulfonic acid and an aldehyde a pharmaceutically acceptable salt or prodrug thereof in a physiologically acceptable carrier.
- 30. A method of claim 29 wherein the condensation polymer is a condensation polymer of a naphthalenesulfonic acid and formaldehyde.
- 31. A method of claim 30 wherein the condensation polymer is a narrow or mono-dispersed condensation polymer.
- 32. The method of claim 30 wherein the condensation polymer has a peak molecular weight of less than about 50 kDa.
- 33. The method of claim 32 wherein the condensation polymer has a peak molecular weight between from about 0.7 kDa and about 50 kDa.
- 34. The method of claim 33 wherein the condensation polymer has a peak molecular weight between from about 1.3 kDa to about 30 kDa.
- 35. The method of claim 34 wherein the condensation polymer has a peak molecular weight between from about 4 kDa to 12 kDa.
- 36. A method of claim 30 wherein the physiologically acceptable carrier is a contraceptive formulation.
- 37. The method of claim 30 wherein the individual is infected by HIV.
- 38. The method of claim 30 wherein the individual has been exposed to HIV.
- 39. A method of inhibiting CD4/gp120 binding in a blood preparation, comprising adding to said blood preparation an effective amount of a composition comprising a condensation polymer of an aromatic sulfonic acid and an aldehyde or a salt thereof in a physiologically acceptable carrier.
- 40. A method of claim 39 wherein the condensation polymer is a condensation polymer of a naphthalenesulfonic acid and formaldehyde.
RELATED APPLICATION
This application is a continuation-in-part of U.S. application Ser. No. 08/245,619 filed May 19, 1994, now U.S. Pat. No. 5,614,559, which is a continuation-in-part of U.S. application Ser. No. 08/156,443 filed Nov. 23, 1993, now abandoned, the entire teachings are incorporated by reference herein.
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
4361547 |
Sipos et al. |
Nov 1982 |
|
4604404 |
Munson, Jr. et al. |
Aug 1986 |
|
5177083 |
Rideout et al. |
Jan 1993 |
|
5308612 |
Lee |
May 1994 |
|
Foreign Referenced Citations (6)
Number |
Date |
Country |
0 384 532 |
Aug 1990 |
EPX |
2 669 535 |
May 1992 |
FRX |
WO9212709 |
Aug 1992 |
WOX |
WO9314146 |
Jul 1993 |
WOX |
WO9403164 |
Feb 1994 |
WOX |
WO9414763 |
Jul 1994 |
WOX |
Non-Patent Literature Citations (3)
Entry |
Taylor, D.L. et al., "Novel Sulphonic Acid Polymers as Inhibitors of HIV Host-Cell Interactions," Abstract PO-B26-2071, IXth International Conference on Aids. Jun. 1993. |
Tan, Ghee T. et al., "Sulfonic acid polymers are potent inhibitors of HIV-1 induced cytopathogenicity and the reverse transcriptases of both HIV-1 and HIV-2," Biochimica et Biophysica Acta, 1181:183-188 1993. |
Mohan, Prem et al., "Sufonic acid polymers as a new class of human immunodeficiency virus inhibitors," Antiviral Research 18:139-150 1992. |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
245619 |
May 1994 |
|
Parent |
156443 |
Nov 1993 |
|